Skip to main content
Top
Published in: Cancer Causes & Control 11/2013

01-11-2013 | Original Paper

Coffee and tea consumption in relation to prostate cancer prognosis

Authors: Milan S. Geybels, Marian L. Neuhouser, Jonathan L. Wright, Marni Stott-Miller, Janet L. Stanford

Published in: Cancer Causes & Control | Issue 11/2013

Login to get access

Abstract

Background

Bioactive compounds found in coffee and tea may delay the progression of prostate cancer.

Methods

We investigated associations of pre-diagnostic coffee and tea consumption with risk of prostate cancer recurrence/progression. Study participants were men diagnosed with prostate cancer in 2002–2005 in King County, Washington, USA. We assessed the usual pattern of coffee and tea consumption two years before diagnosis date. Prostate cancer-specific outcome events were identified using a detailed follow-up survey. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs).

Results

The analysis of coffee intake in relation to prostate cancer recurrence/progression included 630 patients with a median follow-up of 6.4 years, during which 140 prostate cancer recurrence/progression events were recorded. Approximately 61 % of patients consumed at least one cup of coffee per day. Coffee consumption was associated with a reduced risk of prostate cancer recurrence/progression; the adjusted HR for ≥4 cups/day versus ≤1 cup/week was 0.41 (95 % CI: 0.20, 0.81; p for trend = 0.01). Approximately 14 % of patients consumed one or more cups of tea per day, and tea consumption was unrelated to prostate cancer recurrence/progression.

Conclusion

Results indicate that higher pre-diagnostic coffee consumption is associated with a lower risk of prostate cancer recurrence/progression. This finding will require replication in larger studies.
Literature
1.
go back to reference Wilson KM, Kasperzyk JL, Rider JR et al (2011) Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. J Natl Cancer Inst 103:876–884PubMedCrossRef Wilson KM, Kasperzyk JL, Rider JR et al (2011) Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. J Natl Cancer Inst 103:876–884PubMedCrossRef
3.
go back to reference Farah A, Monteiro M, Donangelo CM, Lafay S (2008) Chlorogenic acids from green coffee extract are highly bioavailable in humans. J Nutr 138:2309–2315PubMedCrossRef Farah A, Monteiro M, Donangelo CM, Lafay S (2008) Chlorogenic acids from green coffee extract are highly bioavailable in humans. J Nutr 138:2309–2315PubMedCrossRef
4.
go back to reference Higdon JV, Frei B (2006) Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 46:101–123PubMedCrossRef Higdon JV, Frei B (2006) Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 46:101–123PubMedCrossRef
5.
go back to reference Nkondjock A (2009) Coffee consumption and the risk of cancer: an overview. Cancer Lett 277:121–125PubMedCrossRef Nkondjock A (2009) Coffee consumption and the risk of cancer: an overview. Cancer Lett 277:121–125PubMedCrossRef
6.
go back to reference Yang H, Rouse J, Lukes L et al (2004) Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin Exp Metastasis 21:719–735PubMedCrossRef Yang H, Rouse J, Lukes L et al (2004) Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin Exp Metastasis 21:719–735PubMedCrossRef
7.
go back to reference Higdon JV, Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43:89–143PubMedCrossRef Higdon JV, Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43:89–143PubMedCrossRef
8.
go back to reference Yang CS, Wang H, Li GX, Yang Z, Guan F, Jin H (2011) Cancer prevention by tea: evidence from laboratory studies. Pharmacol Res 64:113–122PubMedCrossRef Yang CS, Wang H, Li GX, Yang Z, Guan F, Jin H (2011) Cancer prevention by tea: evidence from laboratory studies. Pharmacol Res 64:113–122PubMedCrossRef
9.
go back to reference Connors SK, Chornokur G, Kumar NB (2012) New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer 64:4–22PubMedCrossRef Connors SK, Chornokur G, Kumar NB (2012) New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer 64:4–22PubMedCrossRef
10.
go back to reference Henning SM, Wang P, Heber D (2011) Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Mol Nutr Food Res 55:905–920PubMedCrossRef Henning SM, Wang P, Heber D (2011) Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Mol Nutr Food Res 55:905–920PubMedCrossRef
11.
go back to reference Johnson JJ, Bailey HH, Mukhtar H (2010) Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 17:3–13PubMedCrossRef Johnson JJ, Bailey HH, Mukhtar H (2010) Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 17:3–13PubMedCrossRef
12.
go back to reference Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL (2008) Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 168:250–260PubMedCrossRef Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL (2008) Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 168:250–260PubMedCrossRef
13.
go back to reference Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T (1999) Measurement characteristics of the women’s health initiative food frequency questionnaire. Ann Epidemiol 9:178–187PubMedCrossRef Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T (1999) Measurement characteristics of the women’s health initiative food frequency questionnaire. Ann Epidemiol 9:178–187PubMedCrossRef
14.
go back to reference Yuan JM, Sun C, Butler LM (2011) Tea and cancer prevention: epidemiological studies. Pharmacol Res 64:123–135PubMedCrossRef Yuan JM, Sun C, Butler LM (2011) Tea and cancer prevention: epidemiological studies. Pharmacol Res 64:123–135PubMedCrossRef
15.
go back to reference Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRef Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRef
16.
go back to reference Wright JL, Kwon EM, Lin DW et al (2010) CYP17 polymorphisms and prostate cancer outcomes. Prostate 70:1094–1101PubMedCrossRef Wright JL, Kwon EM, Lin DW et al (2010) CYP17 polymorphisms and prostate cancer outcomes. Prostate 70:1094–1101PubMedCrossRef
17.
go back to reference Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515–526CrossRef Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515–526CrossRef
18.
go back to reference Denham JW, Steigler A, Wilcox C et al (2009) Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 115:4477–4487PubMedCrossRef Denham JW, Steigler A, Wilcox C et al (2009) Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 115:4477–4487PubMedCrossRef
19.
go back to reference Arab L, Su LJ, Steck SE et al (2012) Coffee consumption and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Nutr Cancer 64:637–642PubMedCrossRef Arab L, Su LJ, Steck SE et al (2012) Coffee consumption and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Nutr Cancer 64:637–642PubMedCrossRef
20.
go back to reference Geybels MS, Neuhouser ML, Stanford JL. (2012) Associations of tea and coffee consumption with prostate cancer risk. Cancer causes & control: CCC (accepted) Geybels MS, Neuhouser ML, Stanford JL. (2012) Associations of tea and coffee consumption with prostate cancer risk. Cancer causes & control: CCC (accepted)
21.
go back to reference Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS (2012) Coffee consumption and prostate cancer risk: further evidence for inverse relationship. Nutr J 11:42PubMedCrossRef Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS (2012) Coffee consumption and prostate cancer risk: further evidence for inverse relationship. Nutr J 11:42PubMedCrossRef
22.
go back to reference Klotz L (2012) Active surveillance: the canadian experience with an “inclusive approach”. J Natl Cancer Inst Monogr 2012:234–241PubMedCrossRef Klotz L (2012) Active surveillance: the canadian experience with an “inclusive approach”. J Natl Cancer Inst Monogr 2012:234–241PubMedCrossRef
23.
go back to reference Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R (2012) Association of coffee drinking with total and cause-specific mortality. N Engl J Med 366:1891–1904PubMedCrossRef Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R (2012) Association of coffee drinking with total and cause-specific mortality. N Engl J Med 366:1891–1904PubMedCrossRef
24.
go back to reference Hashimoto T, He Z, Ma WY et al (2004) Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res 64:3344–3349PubMedCrossRef Hashimoto T, He Z, Ma WY et al (2004) Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res 64:3344–3349PubMedCrossRef
25.
go back to reference He Z, Ma WY, Hashimoto T, Bode AM, Yang CS, Dong Z (2003) Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res 63:4396–4401PubMed He Z, Ma WY, Hashimoto T, Bode AM, Yang CS, Dong Z (2003) Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res 63:4396–4401PubMed
26.
go back to reference Song F, Qureshi AA, Han J (2012) Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. Cancer Res 72:3282–3289PubMedCrossRef Song F, Qureshi AA, Han J (2012) Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. Cancer Res 72:3282–3289PubMedCrossRef
27.
go back to reference Holick CN, Smith SG, Giovannucci E, Michaud DS (2010) Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies. Cancer Epidemiol Biomarkers Prev 19:39–47PubMedCrossRef Holick CN, Smith SG, Giovannucci E, Michaud DS (2010) Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies. Cancer Epidemiol Biomarkers Prev 19:39–47PubMedCrossRef
28.
go back to reference Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE (2008) Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 112:1169–1177PubMedCrossRef Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE (2008) Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 112:1169–1177PubMedCrossRef
29.
go back to reference Huber WW, Rossmanith W, Grusch M et al (2008) Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol 46:1230–1238PubMedCrossRef Huber WW, Rossmanith W, Grusch M et al (2008) Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol 46:1230–1238PubMedCrossRef
30.
go back to reference Tunnicliffe JM, Shearer J (2008) Coffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators. Appl Physiol Nutr Metab 33:1290–1300PubMedCrossRef Tunnicliffe JM, Shearer J (2008) Coffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators. Appl Physiol Nutr Metab 33:1290–1300PubMedCrossRef
31.
go back to reference Lee WJ, Zhu BT (2006) Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 27:269–277PubMedCrossRef Lee WJ, Zhu BT (2006) Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 27:269–277PubMedCrossRef
32.
go back to reference Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66:1234–1240PubMedCrossRef Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66:1234–1240PubMedCrossRef
Metadata
Title
Coffee and tea consumption in relation to prostate cancer prognosis
Authors
Milan S. Geybels
Marian L. Neuhouser
Jonathan L. Wright
Marni Stott-Miller
Janet L. Stanford
Publication date
01-11-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 11/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0270-5

Other articles of this Issue 11/2013

Cancer Causes & Control 11/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine